Shanghai Henlius Biotech, Inc. (2696.HK)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Jun Zhu | CEO & Executive Director | 9.6M | -- | 1979 |
| Ms. Huang Wei | President | -- | -- | 1969 |
| Dr. Shi-Kau Liu | Co-founder & Head of Strategy Advisory Committee | 6.62M | -- | 1964 |
| Dr. Wei-Dong Jiang | Co-Founder & Co-Head of Innovative Advisory Committee | -- | -- | 1963 |
| Mr. Yingbo Mao | VP & CFO | -- | -- | 1979 |
| Dr. Jijun Yuan | Chief Scientific Officer | -- | -- | 1978 |
| Ms. Miaojie Chen | Vice President of Legal & Compliance | -- | -- | -- |
| Ms. Yan Wang | Deputy GM of Public Relations & Joint Company Secretary | -- | -- | 1988 |
| Mr. Wallis Zeng | VP of Sales & Oncology Business Unit | -- | -- | -- |
| Ms. Junhua Li | Senior VP & Chief Human Resources Officer | -- | -- | 1977 |
Shanghai Henlius Biotech, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 3,515
Description
Shanghai Henlius Biotech, Inc. engages in the research and development of biologic medicines with a focus on oncology, autoimmune diseases, and ophthalmic diseases. It offers HANLIKANG, a rituximab injection for treating active glomerulonephritis; HANQUYOU, a trastuzumab injection to treat breast and metastatic breast, and gastric cancer; HANDAYUAN, an adalimumab injection for the treatment of rheumatoid arthritis, ankylosing spondylitis, psoriasis, uveitis, polyarticular juvenile idiopathic arthritis, pediatric plaque psoriasis, Crohn's disease, and pediatric Crohn's disease; and HANBEITAI, a bevacizumab injection to treat metastatic colorectal cancer (mCRC) and recurrent non-small cell lung cancer. The company also develops HANSIZHUANG, a serplulimab injection to treat colorectal cancer, gastric carcinoma, and limited-stage small cell lung cancer; HLX04-O, an anti-VEGF monoclonal antibody injection for wet age-related macular degeneration; HLX22 to treat of metastatic gastroesophageal junction cancer and gastric cancer; HLX6018 to treat idiopathic pulmonary fibrosis; HLX22, HLX42, HLX43, and HLX53 to treat solid tumors; HLX11 to treat breast cancer; HLX14 to treat osteoporosis; and HLX15 for multiple myeloma. The company operates in Mainland China, the Asia Pacific, North and South America, Europe, and Oceania. The company was founded in 2010 and is headquartered in Shanghai, China.
Corporate Governance
Upcoming Events
March 24, 2025 at 10:41 AM UTC
Shanghai Henlius Biotech, Inc. Earnings Date
Recent Events
Recent Events Information Not Available